Eric Marcusson

Eric Marcusson has over 30 years of experience in the biotechnology industry. Eric began their career in 1990 as a Grad Student at UCSD. In 1996, they joined Isis Pharmaceuticals as a Postdoctoral Fellow, where they investigated the intracellular trafficking pathways of cationic lipids and antisense oligonucleotides after transfection into mammalian cells and dissected receptor-mediated apoptosis pathways with the use of antisense oligonucleotides. Eric then held positions at Immusol as a Research Scientist and Research Scientist II from 1998 to 2000. At Isis Pharmaceuticals from 2000 to 2007, they held various positions such as Director, Antisense Drug Discovery, Associate Director, Antisense Drug Discovery, Assistant Director, Antisense Drug Discovery, and Senior Scientist, GeneTrove Division. Eric also ran the Oncology program and started a program on Nuclear Receptor Comodulators. In 2007, they joined Regulus Therapeutics as Senior Director, Oncology and Basic Mechanisms and Director, Drug Discovery. In 2013, they founded Marcusson Consulting, specializing in all mechanisms of RNA therapeutics and early oncology discovery. In 2019, they became a SAB Member at Deep Genomics and in 2020, they became a SAB Member at ARTHEx Biotech. From 2015 to 2022, they were Co-Founder, Board Member & Chair of the SAB and Co-founder and CSO at Providence Therapeutics. Eric is currently Global Head of RNA & Delivery at Northern RNA Inc.

Eric Marcusson obtained a Ph.D. in Biomedical Sciences from the University of California, San Diego School of Medicine between 1990 and 1995. Prior to that, they obtained a BA - Magna Cum Laude in Cell Biology and Physiological Psychology from UC San Diego between 1983 and 1988.